ProMIS Neurosciences (PMN) Other Non-Current Assets (2021 - 2026)
ProMIS Neurosciences' (PMN) quarterly Other Non-Current Assets came in at $1.8 million in Q1 2026, up 12603.05% on a QoQ basis from $14161.0 in Q4 2023.
ProMIS Neurosciences (PMN) Other Non-Current Assets (2021 - 2026) Analysis & Trends
ProMIS Neurosciences (PMN) has 4 years of Other Non-Current Assets data on file, last reported at $1.8 million in Q1 2026.
- Quarterly Other Non-Current Assets changed N/A year-over-year to $1.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.8 million (changed N/A YoY) and the FY2023 annual result came in at $14161.0, up 9.72% from the prior year.
- Other Non-Current Assets grew to $1.8 million in Q1 2026, from $14161.0 in the prior quarter.
- In the past five years, Other Non-Current Assets ranged from a high of $1.8 million in Q1 2026 to a low of $12711.0 in Q3 2022.
- A 3-year average of $237258.1 and a median of $13419.0 in 2022 frame the typical range for Other Non-Current Assets.
- Annual changes were most pronounced in 2022 — Other Non-Current Assets jumped 88.73% — and 2023, when it fell 2.73%.
- Tracing PMN's Other Non-Current Assets over 3 years: stood at $12907.0 in 2022, then grew by 9.72% to $14161.0 in 2023, then soared by 12603.05% to $1.8 million in 2026.
- The last three Other Non-Current Assets figures came in at $1.8 million (Q1 2026), $14161.0 (Q4 2023), and $19623.0 (Q3 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 2.31 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 124.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 618.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 109.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 65.13 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 202.31 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 104.44 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 62.96 Mn |
| 10 | ProMIS Neurosciences | 132.34 Mn | 78.87 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.80 Mn |
| Dec 31, 2023 | 14,161.00 |
| Sep 30, 2023 | 19,623.00 |
| Jun 30, 2023 | 13,233.00 |
| Mar 31, 2023 | 12,946.00 |
| Dec 31, 2022 | 12,907.00 |
| Sep 30, 2022 | 12,711.00 |
| Jun 30, 2022 | 13,605.00 |
| Dec 31, 2021 | 6,839.00 |